Shots:

• The companies collaborated to evaluate new cancer treatments by combining AdAlta’s CXCR4-inhibiting i-bodies with beta-blockers. AdAlta has a panel of i-bodies that suppress CXCR4 signaling. The panel contains AD-214 for fibrotic disorders that have advanced to clinical development
• AdAlta has the first option to license & commercialize products for cancer that resulted from the collaboration. GPCR has also the same option if it is not exercised by AdAlta
• The combined CXCR4-B2AR inhibition will be tested in future studies to evaluate the effect of in vitro cell signaling, migration, and killing. If the trial is successful, GPCR will test the combined inhibition of these drugs in vivo in animal cancer models

Ref: Pharmiweb | Image: AdAlta